Spikevax

Launch

covid-19 vaccine, mrna

BLAINTRAMUSCULARINJECTION, SUSPENSION
Approved
Aug 2025
Lifecycle
Launch
Competitive Pressure
30/100
Clinical Trials
3

Clinical Trials (3)

NCT06333704N/ARecruiting

Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT and SPIKEVAX X Injection.

Started Mar 2023
4,206 enrolled
SARS-CoV-2
NCT06369272N/ACompleted

Study to Assess Maternal and Infant Outcomes Following Exposure to SPIKEVAX During Pregnancy

Started Mar 2023
1,192 enrolled
Maternal OutcomesInfant OutcomesPregnancy
NCT06189053N/AActive Not Recruiting

A Study to Assess Long-term Outcomes of Myocarditis Following Administration of COVID-19 mRNA Vaccine (SPIKEVAX)

Started Apr 2022
1,500 enrolled
Myocarditis